158 related articles for article (PubMed ID: 23158991)
1. [Expression and significance of Twist1 and MMP-2 in endometrial endometrioid adenocarcinoma].
Wang XJ; Chen XH
Zhonghua Zhong Liu Za Zhi; 2012 Aug; 34(8):588-91. PubMed ID: 23158991
[TBL] [Abstract][Full Text] [Related]
2. Progesterone receptor negativity is an independent risk factor for relapse in patients with early stage endometrioid endometrial adenocarcinoma.
Huvila J; Talve L; Carpén O; Edqvist PH; Pontén F; Grénman S; Auranen A
Gynecol Oncol; 2013 Sep; 130(3):463-9. PubMed ID: 23777659
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of matrix metalloproteinase-2 (MMP-2) expression in endometrial endometrioid adenocarcinoma.
Talvensaari-Mattila A; Santala M; Soini Y; Turpeenniemi-Hujanen T
Anticancer Res; 2005; 25(6B):4101-5. PubMed ID: 16309203
[TBL] [Abstract][Full Text] [Related]
4. [Relationship between the expression of dual specificity phosphatase-1 and the prognosis of endometrioid adenocarcinoma].
Gao BR; Yao YY; Chen YH; Li XP; Wang JL; Wei LH
Zhonghua Yi Xue Za Zhi; 2013 Aug; 93(31):2493-5. PubMed ID: 24300273
[TBL] [Abstract][Full Text] [Related]
5. Tumor-infiltrating dendritic cells may be used as clinicopathologic prognostic factors in endometrial carcinoma.
Lijun Z; Xin Z; Danhua S; Xiaoping L; Jianliu W; Huilan W; Lihui W
Int J Gynecol Cancer; 2012 Jun; 22(5):836-41. PubMed ID: 22617481
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of Twist, E-cadherin, and N-cadherin protein expression in endometrioid adenocarcinoma.
Xie X; Zheng X; Wang J; Chen L
J Cancer Res Ther; 2017; 13(5):817-822. PubMed ID: 29237910
[TBL] [Abstract][Full Text] [Related]
7. Matrix metalloproteinases 2 and 9, E-cadherin, and beta-catenin expression in endometriosis, low-grade endometrial carcinoma and non-neoplastic eutopic endometrium.
Shaco-Levy R; Sharabi S; Benharroch D; Piura B; Sion-Vardy N
Eur J Obstet Gynecol Reprod Biol; 2008 Aug; 139(2):226-32. PubMed ID: 18295959
[TBL] [Abstract][Full Text] [Related]
8. Ovarian preservation in young women with endometrial cancer of endometrioid histology.
Kinjyo Y; Kudaka W; Ooyama T; Inamine M; Nagai Y; Aoki Y
Acta Obstet Gynecol Scand; 2015 Apr; 94(4):430-4. PubMed ID: 25603833
[TBL] [Abstract][Full Text] [Related]
9. Risk factors for ovarian involvement in young and premenopausal endometrioid endometrial cancer patients.
Li J; Zhu Q; Yang B; Ning C; Liu X; Luo X; Chen X
Eur J Obstet Gynecol Reprod Biol; 2018 Mar; 222():151-154. PubMed ID: 29408747
[TBL] [Abstract][Full Text] [Related]
10. Histological features associated with occult lymph node metastasis in FIGO clinical stage I, grade I endometrioid carcinoma.
Han G; Lim D; Leitao MM; Abu-Rustum NR; Soslow RA
Histopathology; 2014 Feb; 64(3):389-98. PubMed ID: 24215212
[TBL] [Abstract][Full Text] [Related]
11. Tumor budding and E-Cadherin expression in endometrial carcinoma: are they prognostic factors in endometrial cancer?
Koyuncuoglu M; Okyay E; Saatli B; Olgan S; Akin M; Saygili U
Gynecol Oncol; 2012 Apr; 125(1):208-13. PubMed ID: 22198340
[TBL] [Abstract][Full Text] [Related]
12. TWIST1 expression and clinical significance in type I endometrial cancer and premalignant lesions: A retrospective clinical study.
Shen J; Chen Q; Li N; Bai X; Wang F; Li B
Medicine (Baltimore); 2020 Nov; 99(48):e23397. PubMed ID: 33235117
[TBL] [Abstract][Full Text] [Related]
13. An intensive follow-up does not change survival of patients with clinical stage I endometrial cancer.
Gadducci A; Cosio S; Fanucchi A; Cristofani R; Genazzani AR
Anticancer Res; 2000; 20(3B):1977-84. PubMed ID: 10928137
[TBL] [Abstract][Full Text] [Related]
14. Clinical characteristics of prognostic factors in poorly differentiated (G3) endometrioid adenocarcinoma in Japan.
Kuwabara Y; Susumu N; Banno K; Hirao T; Kawaguchi M; Yamagami W; Suzuki N; Aoki D; Nozawa S
Jpn J Clin Oncol; 2005 Jan; 35(1):23-7. PubMed ID: 15681600
[TBL] [Abstract][Full Text] [Related]
15. Cyr61, a member of ccn (connective tissue growth factor/cysteine-rich 61/nephroblastoma overexpressed) family, predicts survival of patients with endometrial cancer of endometrioid subtype.
Watari H; Xiong Y; Hassan MK; Sakuragi N
Gynecol Oncol; 2009 Jan; 112(1):229-34. PubMed ID: 19007976
[TBL] [Abstract][Full Text] [Related]
16. Role of SUVmax and GLUT-1 Expression in Determining Tumor Aggressiveness in Patients With Clinical Stage I Endometrioid Endometrial Cancer.
Lee DW; Chong GO; Lee YH; Hong DG; Cho YL; Jeong SY; Park JY; Lee YS
Int J Gynecol Cancer; 2015 Jun; 25(5):843-9. PubMed ID: 25347093
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of overexpression of p53 in uterine endometrioid adenocarcinomas with an analysis of nuclear grade.
Urabe R; Hachisuga T; Kurita T; Kagami S; Kawagoe T; Matsuura Y; Shimajiri S
J Obstet Gynaecol Res; 2014 Mar; 40(3):812-9. PubMed ID: 24246002
[TBL] [Abstract][Full Text] [Related]
18. MMP-2, TIMP-1, E-cadherin, and beta-catenin expression in endometrial serous carcinoma compared with low-grade endometrial endometrioid carcinoma and proliferative endometrium.
Shaco-Levy R; Sharabi S; Piura B; Sion-Vardy N
Acta Obstet Gynecol Scand; 2008; 87(8):868-74. PubMed ID: 18607832
[TBL] [Abstract][Full Text] [Related]
19. [Expression of P53, P63, and C-erbB-2 in endometrioid adenocarcinoma and their clinicopathological significance].
Hu WF; Liu MQ; Zhao Q
Ai Zheng; 2004 Sep; 23(9):1021-5. PubMed ID: 15363194
[TBL] [Abstract][Full Text] [Related]
20. COX-2 and survivin are overexpressed and positively correlated in endometrial carcinoma.
Erkanli S; Bolat F; Kayaselcuk F; Demirhan B; Kuscu E
Gynecol Oncol; 2007 Feb; 104(2):320-5. PubMed ID: 17030351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
